Developing next-generation vaccines against respiratory pathogens
The Novo Nordisk Foundation Vaccine Accelerator (NVAC) is part of the Novo Nordisk Foundation Initiative for Vaccines & Immunity (NIVI). NVAC enables the translational efforts of NIVI by providing industry-level expertise in vaccine development and conducting clinical studies for new vaccine candidates.
About us
Bridging research, translational sciences, and development
NVAC will catalyse progress towards achieving the NIVI mission by enabling access to cutting-edge technologies and data-driven approaches to design, test, and optimise novel vaccine candidates. NVAC provides capabilities and expertise – either directly, or via external strategic partnerships – to bridge exploratory research and clinical (Phase 1 & 2, including CHIM) translational development.
Harnessing airway immunity: Innovative vaccine research and development to prevent airborne epidemics
A major new vaccines research initiative launched in 2024
The Novo Nordisk Foundation Initiative for Vaccines & Immunity (NIVI) generates knowledge on host immunity, host-pathogen interactions, and vaccine technologies, and translates this knowledge into vaccines that provide robust, durable, and broad immunity against respiratory pathogens.
News
May 2024: Dr Nicholas Jackson announced as CEO of NVAC
Nicholas Jackson has over 25 years of experience in infectious diseases, vaccines, and immunotherapeutics. He has worked in the UK, Belgium, USA, and France for several multinational companies and public health institutions, and has led global programs from early research through to Phase 3, licensure, and post-licensure. His appointment is an important milestone in NIVI’s journey towards revolutionising vaccine development and combatting respiratory infections.
